| Year |
Citation |
Score |
| 2021 |
Ruchert JM, Brady MM, McMahan S, Lacey KJ, Latta LC, Sekelsky J, Stoffregen EP. Blm helicase facilitates rapid replication of repetitive DNA sequences in early Drosophila development. Genetics. PMID 34849849 DOI: 10.1093/genetics/iyab169 |
0.616 |
|
| 2013 |
Donley N, Stoffregen EP, Smith L, Montagna C, Thayer MJ. Asynchronous replication, mono-allelic expression, and long range Cis-effects of ASAR6. Plos Genetics. 9: e1003423. PMID 23593023 DOI: 10.1371/journal.pgen.1003423 |
0.428 |
|
| 2011 |
Stoffregen EP, Donley N, Stauffer D, Smith L, Thayer MJ. An autosomal locus that controls chromosomewide replication timing and mono-allelic expression Human Molecular Genetics. 20: 2366-2378. PMID 21459774 DOI: 10.1093/hmg/ddr138 |
0.399 |
|
| 2006 |
Tyner JW, Eide CA, Stoffregen EP, Loriaux M, Willis SG, Gattermann N, Kovacsovics T, Druker BJ, Deininger MW. Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia. Blood. 108: 3606-3606. DOI: 10.1182/Blood.V108.11.3606.3606 |
0.304 |
|
| 2005 |
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 106: 3377-9. PMID 16081687 DOI: 10.1182/Blood-2005-05-1898 |
0.323 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2008 |
Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/Blood-2007-07-101394 |
0.28 |
|
| 2005 |
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 106: 2128-37. PMID 15914554 DOI: 10.1182/Blood-2005-03-1036 |
0.272 |
|
| 2014 |
LaFave MC, Andersen SL, Stoffregen EP, Holsclaw JK, Kohl KP, Overton LJ, Sekelsky J. Sources and structures of mitotic crossovers that arise when BLM helicase is absent in Drosophila. Genetics. 196: 107-18. PMID 24172129 DOI: 10.1534/Genetics.113.158618 |
0.238 |
|
| 2003 |
Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 101: 4611-4. PMID 12576318 DOI: 10.1182/Blood-2002-12-3659 |
0.228 |
|
| 2006 |
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Molecular and Cellular Biology. 26: 6082-6093. PMID 16880519 DOI: 10.1182/Blood.V108.11.4796.4796 |
0.227 |
|
| 2006 |
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10: 65-75. PMID 16843266 DOI: 10.1016/J.Ccr.2006.06.002 |
0.222 |
|
| 2005 |
Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O'Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MWN. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib Leukemia. 19: 1859-1862. PMID 16151465 DOI: 10.1038/Sj.Leu.2403935 |
0.217 |
|
| 2005 |
Crossman LC, O’Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O’Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW. A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors. Blood. 106: 1530-1530. DOI: 10.1182/Blood.V106.11.1530.1530 |
0.215 |
|
| 2004 |
O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 104: 2532-9. PMID 15256422 DOI: 10.1182/Blood-2004-05-1851 |
0.187 |
|
| 2003 |
La Rosée P, Shen L, Stoffregen EP, Deininger M, Druker BJ. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). The Hematology Journal : the Official Journal of the European Haematology Association. 4: 413-9. PMID 14671613 DOI: 10.1038/Sj.Thj.6200297 |
0.186 |
|
| 2002 |
La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Research. 62: 7149-53. PMID 12499247 |
0.166 |
|
| 2005 |
Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood. 105: 2952-4. PMID 15585651 DOI: 10.1182/Blood-2004-07-2758 |
0.163 |
|
| 2005 |
O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research. 65: 4500-5. PMID 15930265 DOI: 10.1158/0008-5472.Can-05-0259 |
0.161 |
|
| 2005 |
O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6987-93. PMID 16203792 DOI: 10.1158/1078-0432.Ccr-05-0622 |
0.13 |
|
| 2004 |
La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood. 103: 208-15. PMID 12933582 DOI: 10.1182/Blood-2003-04-1074 |
0.128 |
|
| 2006 |
Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leukemia Research. 30: 1097-104. PMID 16464493 DOI: 10.1016/J.Leukres.2006.01.001 |
0.125 |
|
| Hide low-probability matches. |